Latest revenue
$9.9M
as of 2026-03-31
Latest net income
$-18.9M
as of 2026-03-31
Net margin
-189.8%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ASRT is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $151.5M
- Enterprise value
- $159.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.00×
- Dividend yield
- 0.0%
- 52-wk high
- $23.47
- 52-wk low
- $0.60
- Beta
- —
- Shares out
- 6.5M
5-year trend
What this company does
ITEM 1. BUSINESS Overview Unless otherwise noted or required by context, use of “Assertio,” the “Company,” “we,” “our” and “us” refer to Assertio Holdings and/or its applicable subsidiary or subsidiaries. Reference to “Assertio Specialty” refers to Assertio Specialty Pharmaceuticals, LLC, and “Spectrum” refers to Spectrum Pharmaceuticals, Inc. and/or its applicable subsidiary or subsidiaries. Both Assertio Specialty and Spectrum are wholly-owned subsidiaries of the Company. Additionally, the use of “Assertio Therapeutics” refers to Assertio Therapeutics, Inc., and/or its applicable subsidiary or subsidiaries. Assertio Therapeutics was divested on May 9, 2025. We are a pharmaceutical company…
AI summary unavailable — showing raw filing excerpt
Generated from ASRT's filing dated 2026-03-16
Key risks
ITEM 1A. RISK FACTORS In addition to other information in this Annual Report on Form 10-K, please consider the following discussion of factors that make an investment in our securities risky. The risks or uncertainties described in this Annual Report on Form 10‑K can materially and adversely affect our business, reputation, stock price, results of operations, cash flows or financial condition. While the risks and uncertainties described below have been grouped under general risk categories, one or more of the categories may be applicable to the risk factors described. The risks and uncertainties described in this Annual Report on Form 10‑K are not the only ones facing us. Additional risks…
AI summary unavailable — showing raw filing excerpt
Generated from ASRT's filing dated 2026-03-16
Profitability
Operating margin
-18.1%
7.4%Net margin
-25.6%
48.2%Return on equity
-32.3%
81.4%Return on assets
-11.4%
50.1%Leverage
Debt / equity
1.84×
36.3%Long-term debt / equity
0.42×
29.9%Debt / assets
64.8%
12.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $9.9M | -62.5% | $-18.9M | -39.3% | -189.8% |
Q4 2025 2025-12-31 | $13.5M | -57.9% | $-11.9M | -13.9% | -88.1% |
Q3 2025 2025-09-30 | $49.5M | +69.4% | $11.4M | +491.8% | 23.1% |
Q2 2025 2025-06-30 | $29.2M | -6.1% | $-16.4M | -345.1% | -56.0% |
Q1 2025 2025-03-31 | $26.5M | -18.4% | $-13.5M | -200.2% | -51.1% |
Q4 2024 2024-12-31 | $32.2M | — | $-10.5M | — | -32.6% |
Q3 2024 2024-09-30 | $29.2M | -18.0% | $-2.9M | +98.9% | -10.0% |
Q2 2024 2024-06-30 | $31.1M | -24.1% | $-3.7M | -173.7% | -11.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ASRT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$6.8K
Net activity
−$6.8K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ASRT
Institutional value
$16.1M
Total shares held
849.4K
Distinct holders
35
-18 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 269.0K | $5.1M | — | New |
| 2 | Walleye Capital LLC | 131.9K | $2.5M | — | New |
| 3 | BlackRock, Inc. | 90.0K | $1.7M | +1 (+0.0%) | Added |
| 4 | JANE STREET GROUP, LLC | 79.4K | $1.5M | +67.6K (+570.9%) | Added |
| 5 | SEI INVESTMENTS CO | 54.9K | $1.0M | — | New |
| 6 | Huntleigh Advisors, Inc. | 52.6K | $1.0M | — | New |
| 7 | EAM Investors, LLC | 45.1K | $860.5K | — | New |
| 8 | CM Management, LLC | 35.0K | $667.1K | -15.0K (-30.0%) | Trimmed |
| 9 | VANGUARD FIDUCIARY TRUST CO | 34.4K | $655.4K | — | New |
| 10 | TSP Capital Management Group, LLC | 25.1K | $477.6K | +0 (+0.0%) | No change |
| 11 | DIMENSIONAL FUND ADVISORS LP | 14.1K | $269.4K | — | New |
| 12 | UBS Group AG | 6.3K | $120.7K | +5.4K (+569.9%) | Added |
| 13 | THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 4.5K | $85.7K | +0 (+0.0%) | No change |
| 14 | Vanguard Global Advisers, LLC | 2.1K | $39.4K | — | New |
| 15 | CITIGROUP INC | 325 | $6.2K | — | New |
| 16 | MCF Advisors LLC | 100 | $1.9K | — | New |
| 17 | WELLS FARGO & COMPANY/MN | 100 | $1.9K | +18 (+22.0%) | Added |
| 18 | JPMORGAN CHASE & CO | 88 | $1.6K | +0 (+0.0%) | No change |
| 19 | Annis Gardner Whiting Capital Advisors, LLC | 80 | $1.5K | — | New |
| 20 | SRS Capital Advisors, Inc. | 63 | $1.2K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ASRT's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.